A New Heart Scan Method to Guide Pacemaker Treatment for Heart Failure
Tests a heart scan measure to help choose adults with heart failure for pacemaker treatment.
Plain-language title generated from the registry record
Registry title: A Study Testing a New Heart Scan Method to Improve Pacemaker Treatment for Heart Failure
Key facts
- Where
- London, United KingdomSee the site
Where in United Kingdom
- Guy's and St Thomas' NHS Foundation TrustLondon, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- King's College London
- Trial code
- NCT07084467
- Record updated
- 3 August 2025
- Original description
Cardiac resynchronization therapy (CRT) is a device treatment for patients with heart failure which cannot be managed by medications alone. CRT can help the heart contract more efficiently and improve the pumping function. However, many patients do not benefit from this treatment. Therefore, a better selection tool will help us to determine the most suitable patients to receive this treatment. A new measure of pumping function of the heart called: first-phase ejection fraction or EF1 has been shown a good tool to select suitable patients for CRT. EF1 is a sensitive measurement of heart function and can be easily measured by echocardiography (an ultrasound heart scan).Read full original descriptionShow less
Evaluation of First-Phase Ejection Fraction to Guide Cardiac Resynchronization Therapy - A Randomised Controlled Trial
Cardiac resynchronization therapy (CRT) is a device treatment for patients with heart failure which cannot be managed by medications alone. CRT can help the heart contract more efficiently and improve the pumping function. However, many patients do not benefit from this treatment. Therefore, a better selection tool will help us to determine the most suitable patients to receive this treatment. A new measure of pumping function of the heart called: first-phase ejection fraction or EF1 has been shown a good tool to select suitable patients for CRT. EF1 is a sensitive measurement of heart function and can be easily measured by echocardiography (an ultrasound heart scan).
The purpose of this study is to examine whether this new measurement (EF1) can predict outcomes and response to CRT treatment.
Inclusion: Age 18 years or older; On optimal medical therapy for heart failure; Meets standard guideline criteria for CRT (including conduction system pacing), specifically:; NYHA class II to IV; Left ventricular ejection fraction (EF) ≤ 35%; QRS duration > 130 ms.
Exclusion: Receiving continuous or intermittent infusion therapy for heart failure; Co-morbidities likely to reduce life expectancy to less than 6 months; Major cardiovascular event within the past 6 weeks; More than mild aortic stenosis; Poor ultrasound acoustic window preventing adequate imaging; Unable to give informed consent; Currently participating in another interventional study.